4D Molecular Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
4D Molecular Therapeutics, Inc. (FDMT) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $809.00K, a 12.05% increase year-over-year.
- 4D Molecular Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $786.00K, a 11.81% increase year-over-year.
- 4D Molecular Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $764.00K, a 11.05% increase year-over-year.
- 4D Molecular Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $742.00K, a 44.64% increase year-over-year.
- 4D Molecular Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $2.93M, a 42.84% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $2.05M, a 32.82% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.54M, a 4.60% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.48M, a 1.34% decline from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $809.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.59M 10-Q · filed 2026-08-13 | $2.36M derived: sum of 3 quarters · filed 2026-08-13 | $3.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $786.00K 10-Q · filed 2026-05-07 | $1.55M derived: sum of 2 quarters · filed 2026-05-07 | $2.29M derived: sum of 3 quarters · filed 2026-05-07 | $3.01M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $764.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $1.51M derived: sum of 2 quarters · filed 2026-03-18 | $2.23M derived: sum of 3 quarters · filed 2026-08-13 | $2.93M 10-K · filed 2026-03-18 |
| 2025-09-30 | $742.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.46M derived: sum of 2 quarters · filed 2026-08-13 | $2.17M 10-Q · filed 2025-11-10 | $2.85M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $722.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.43M 10-Q · filed 2026-08-13 | $2.11M derived: sum of 3 quarters · filed 2026-08-13 | $2.63M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $703.00K 10-Q · filed 2026-05-07 | $1.39M derived: sum of 2 quarters · filed 2026-05-07 | $1.90M derived: sum of 3 quarters · filed 2026-05-07 | $2.33M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $688.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $1.20M derived: sum of 2 quarters · filed 2026-03-18 | $1.63M derived: sum of 3 quarters · filed 2026-03-18 | $2.05M 10-K · filed 2026-03-18 |
| 2024-09-30 | $513.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $943.00K derived: sum of 2 quarters · filed 2025-11-10 | $1.36M 10-Q · filed 2025-11-10 | $1.77M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $430.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $851.00K 10-Q · filed 2025-08-11 | $1.26M derived: sum of 3 quarters · filed 2025-08-11 | $1.66M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $421.00K 10-Q · filed 2025-05-08 | $832.00K derived: sum of 2 quarters · filed 2025-05-08 | $1.23M derived: sum of 3 quarters · filed 2025-05-08 | $1.58M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $411.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $813.00K derived: sum of 2 quarters · filed 2025-02-28 | $1.16M derived: sum of 3 quarters · filed 2025-02-28 | $1.54M 10-K · filed 2025-02-28 |
| 2023-09-30 | $402.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $751.00K derived: sum of 2 quarters · filed 2024-11-13 | $1.13M 10-Q · filed 2024-11-13 | $1.51M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $349.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $732.00K 10-Q · filed 2024-08-08 | $1.11M derived: sum of 3 quarters · filed 2024-08-08 | $1.47M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $383.00K 10-Q · filed 2024-05-09 | $757.00K derived: sum of 2 quarters · filed 2024-05-09 | $1.12M derived: sum of 3 quarters · filed 2024-05-09 | $1.48M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $374.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $736.00K derived: sum of 2 quarters · filed 2024-02-29 | $1.10M derived: sum of 3 quarters · filed 2024-02-29 | $1.48M 10-K · filed 2024-02-29 |
| 2022-09-30 | $362.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $727.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.10M 10-Q · filed 2023-11-09 | $1.48M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $365.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $741.00K 10-Q · filed 2023-08-09 | $1.12M derived: sum of 3 quarters · filed 2023-08-09 | $1.50M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $376.00K 10-Q · filed 2023-05-11 | $756.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.14M derived: sum of 3 quarters · filed 2023-05-11 | $1.51M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $380.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $760.00K derived: sum of 2 quarters · filed 2023-03-15 | $1.13M derived: sum of 3 quarters · filed 2023-03-15 | $1.50M 10-K · filed 2023-03-15 |
| 2021-09-30 | $380.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $752.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.12M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $372.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $737.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $365.00K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |